Asia
China continues to be a hotbed of investment for U.S. pharmaceutical and biotech companies. Last week BioSpace reported that China expects to see exponential industry growth by 2022 and today Eli Lilly and Company added to that growth through a partnership with China’s National Center for Cardiovascular Diseases.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.
Recently, Dr. Wang discussed China life science with partneringNEWS, a publication of EBD Group. ChinaBio and EBD will hold the tenth iteration of the ChinaBio Partnering Forum in Suzhou, China on April 25-26, 2018.
Teva got a nice shot in the arm after reports that billionaire investor Warren Buffett took a stake in the company.
Hayao will also form a JV with GNC to make and distribute GNC supplements in China.
The company reported positive results from early studies in 35 patients with a type of blood cancer last year.
InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research.
Beijing’s Tsinghua University will invest $276M in a JV to build a new biohub in the UK’s Cambridge Science Park.
The federal watchdog has cleared the updated design and labeling for the duodenoscope.
PRESS RELEASES